{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:57Z","timestamp":1791300537284,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,5,6]],"date-time":"2006-05-06T00:00:00Z","timestamp":1146873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2007,2,2]]},"DOI":"10.1007\/s10067-006-0299-x","type":"journal-article","created":{"date-parts":[[2006,5,5]],"date-time":"2006-05-05T05:37:35Z","timestamp":1146807455000},"page":"335-341","source":"Crossref","is-referenced-by-count":30,"title":["Rheumatologic aspects of lysosomal storage diseases"],"prefix":"10.1007","volume":"26","author":[{"given":"Bernhard","family":"Manger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland M.","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,5,6]]},"reference":[{"key":"299_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE et al (1999) Prevalence of lysosomal storage disorders. JAMA 281:249\u2013254","journal-title":"JAMA"},{"key":"299_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151\u2013156","journal-title":"Hum Genet"},{"key":"299_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/bcmd.1998.0165","volume":"24","author":"E Beutler","year":"1998","unstructured":"Beutler E, Gelbart T (1998) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 24:2\u20138","journal-title":"Blood Cells Mol Dis"},{"key":"299_CR4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0300-9084(72)80173-1","volume":"54","author":"RO Brady","year":"1972","unstructured":"Brady RO (1972) Lipidoses. Biochimie 54:723\u2013733","journal-title":"Biochimie"},{"key":"299_CR5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.1365-2141.1997.d01-2076.x","volume":"96","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Levi M, Berends F et al (1997) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96:470\u2013476","journal-title":"Br J Haematol"},{"key":"299_CR6","first-page":"388","volume":"106","author":"Y Shoenfeld","year":"1982","unstructured":"Shoenfeld Y, Gallant LA, Shaklai M et al (1982) Gaucher\u2019s disease: a disease with chronic stimulation of the immune system. Arch Pathol Lab Med 106:388\u2013391","journal-title":"Arch Pathol Lab Med"},{"key":"299_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","volume":"103","author":"RG Boot","year":"2004","unstructured":"Boot RG, Verhoek M, de Fost M et al (2004) Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103:33\u201339","journal-title":"Blood"},{"key":"299_CR8","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P et al (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160:2835\u20132843","journal-title":"Arch Intern Med"},{"key":"299_CR9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.1780250616","volume":"25","author":"Z Weizman","year":"1982","unstructured":"Weizman Z, Tennenbaum A, Yatziv S (1982) Interphalangeal joint involvement in Gaucher\u2019s disease, type I, resembling juvenile rheumatoid arthritis. Arthritis Rheum 25:706\u2013707","journal-title":"Arthritis Rheum"},{"key":"299_CR10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med 324:1464\u20131470","journal-title":"N Engl J Med"},{"key":"299_CR11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpeds.2003.10.067","volume":"144","author":"J Charrow","year":"2004","unstructured":"Charrow J, Andersson HC, Kaplan P et al (2004) Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 144:112\u2013120","journal-title":"J Pediatr"},{"key":"299_CR12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/PL00002150","volume":"96","author":"C Niederau","year":"2001","unstructured":"Niederau C, Rolfs A, vom Dahl S et al (2001) Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000. Med Klin (Munich) 96:32\u201339","journal-title":"Med Klin (Munich)"},{"key":"299_CR13","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited disease","author":"R Desnick","year":"2001","unstructured":"Desnick R, Ioannou Y, Eng C (2001) Alpha-galactosidase A deficiency: Fabry disease. In: The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 3733\u20133774"},{"key":"299_CR14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769\u2013775","journal-title":"J Med Genet"},{"key":"299_CR15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","volume":"324","author":"W Scheidt von","year":"1991","unstructured":"von Scheidt W, Eng CM, Fitzmaurice TF et al (1991) An atypical variant of Fabry\u2019s disease with manifestations confined to the myocardium. N Engl J Med 324:395\u2013399","journal-title":"N Engl J Med"},{"key":"299_CR16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338\u2013346","journal-title":"Ann Intern Med"},{"key":"299_CR17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","volume":"13","author":"K Lee","year":"2003","unstructured":"Lee K, Jin X, Zhang K et al (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13:305\u2013313","journal-title":"Glycobiology"},{"key":"299_CR18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CE, Donker-Koopman WE et al (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66:1589\u20131595","journal-title":"Kidney Int"},{"key":"299_CR19","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA III et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"key":"299_CR20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"299_CR21","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB et al (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933\u20131946","journal-title":"Kidney Int"},{"key":"299_CR22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"},{"key":"299_CR23","first-page":"3421","volume-title":"The metabolic and molekular bases of inherited disease","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J (2001) The mucopolysaccharidosis. In: Scriver CR, Beaudet AL, Valle D, Sly WS (eds) The metabolic and molekular bases of inherited disease. McGraw Hill, New York, pp 3421\u20133452"},{"key":"299_CR24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1651-2227.1995.tb13640.x","volume":"84","author":"MA Cleary","year":"1995","unstructured":"Cleary MA, Wraith JE (1995) The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr 84:337\u2013339","journal-title":"Acta Paediatr"},{"key":"299_CR25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0925-4439(03)00129-7","volume":"1639","author":"LK Hein","year":"2003","unstructured":"Hein LK, Hopwood JJ, Clements PR et al (2003) The alpha-L-iduronidase mutations R89Q and R89W result in an attenuated mucopolysaccharidosis type I clinical presentation. Biochim Biophys Acta 1639:95\u2013103","journal-title":"Biochim Biophys Acta"},{"key":"299_CR26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13638490310001654763","volume":"7","author":"HM Dumas","year":"2004","unstructured":"Dumas HM, Fragala MA, Haley SM et al (2004) Physical performance testing in mucopolysaccharidosis I: a pilot study. Pediatr Rehabil 7:125\u2013131","journal-title":"Pediatr Rehabil"},{"key":"299_CR27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0002-9149(03)00909-3","volume":"92","author":"EA Braunlin","year":"2003","unstructured":"Braunlin EA, Stauffer NR, Peters CH et al (2003) Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol 92:882\u2013886","journal-title":"Am J Cardiol"},{"key":"299_CR28","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1056\/NEJMoa032613","volume":"350","author":"SL Staba","year":"2004","unstructured":"Staba SL, Escolar ML, Poe M et al (2004) Cord-blood transplants from unrelated donors in patients with Hurler\u2019s syndrome. N Engl J Med 350:1960\u20131969","journal-title":"N Engl J Med"},{"key":"299_CR29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144:581\u2013588","journal-title":"J Pediatr"},{"key":"299_CR30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/14656566.6.3.489","volume":"6","author":"JE Wraith","year":"2005","unstructured":"Wraith JE (2005) The first 5\u00a0years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6:489\u2013506","journal-title":"Expert Opin Pharmacother"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-006-0299-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-006-0299-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:50:59Z","timestamp":1559105459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-006-0299-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,2,2]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1007\/s10067-006-0299-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,6]]}}}